Three patients (3 female patients; aged 7, 35, and 61 years) who had recalcitrant idiopathic sclerosing orbital inflammation were treated with rituximab. The disease was bilateral in 1 patient (4 orbits in total): diffuse in 2 and localized in 2 orbits. It caused optic neuropathy in 1 orbit of each patient. Conventional immunotherapy and tumor debulking surgery were unsuccessful in controlling the disease. After rituximab infusions (375 mg/m2/week for 4 weeks), all patients improved symptomatically. Radiologically, the local lesions resolved completely and diffuse lesions partially. Two patients with recurrent inflammation during follow up (78, 58, and 51 months) responded well to immediate, short-term steroid treatments. Short-term rituximab therapy can induce effective remissions in patients with refractory idiopathic sclerosing orbital inflammation. Early and local lesions may respond better to treatment than diffuse lesions. Nevertheless, inflammatory exacerbations can occur during late follow up.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IOP.0000000000001843 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case Series and Brief Review of Literature on Encapsulating Peritoneal Sclerosis: Unveiling the Cocoon.
Cureus
November 2024
Radiodiagnosis, Amrita Institute of Medical Sciences, Kochi, IND.
This case series explores four distinct instances of encapsulating peritoneal sclerosis (EPS), a rare but serious condition characterized by the encapsulation of abdominal viscera, commonly referred to as abdominal cocoon. EPS is associated with severe complications, including bowel obstruction and sepsis, which can significantly impact patient outcomes. The first case involves a 41-year-old male patient who had undergone a liver transplant and ultimately succumbed to extensively drug-resistant (XDR) sepsis.
View Article and Find Full Text PDFRacial Disparities in Inpatient Hospital Outcomes of Primary Sclerosing Cholangitis in United States: Nationwide Analysis.
Diagnostics (Basel)
November 2024
Parkview Cancer Institute, Advanced Interventional Endoscopy & Endoscopic Oncology (IOSE) Division, GI Oncology Program, 11104 Parkview Circle, Suite 310, Fort Wayne, IN 46845, USA.
Article Synopsis
- Primary sclerosing cholangitis (PSC) is a liver disease linked to inflammatory bowel disease and can cause serious liver complications; this study investigates trends in healthcare usage and mortality related to PSC in the U.S. from 2008 to 2017.
- The analysis of the Nationwide Inpatient Sample reveals that while hospital charges for PSC patients rose by 32.2%, the average length of hospital stays decreased during the study period, indicating changes in healthcare practices.
- Additionally, there was a notable increase in the severity of illness and risk of death among PSC patients, with a rise in cases of hepatocellular carcinoma (HCC), while cases of cholangiocarcinoma (CCA) saw a decline.
Benign Tumors and Tumor-Like Conditions of Ampulla and Small Intestine: The PathologyOutlines.com Review.
Int J Surg Pathol
October 2024
PathologyOutlines.com Owner and Founder.
Article Synopsis
- The small intestine and ampulla can develop various benign tumors and tumor-like diseases that may resemble cancer, highlighting the need for pathologists to have a comprehensive understanding of these conditions.
- Key examples of these benign issues include Brunner gland lesions, different types of polyps, and various mesenchymal proliferations like inflammatory fibroid polyps and leiomyomas.
- The review aims to clarify the histopathological features of these benign conditions to aid pathologists in making accurate diagnoses and differentiating them from malignant tumors.
The risk of cancer in pediatric-onset immune-mediated inflammatory diseases - A nationwide study.
J Autoimmun
December 2024
Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital, Amager and Hvidovre Hospital, Hvidovre, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents, and Adults, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark; Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital -Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Departments of Epidemiology and Global Health, Boston University School of Public Health, Boston, USA; Copenhagen Health Complexity Center, Department of Public Health, University of Copenhagen, Copenhagen, Denmark. Electronic address:
Article Synopsis
- Pediatric-onset immune-mediated inflammatory disease (pIMID) significantly raises the long-term risk of various cancers compared to non-affected individuals, with a twofold increase in cancer risk observed.
- A study involving 12,664 pIMID patients revealed that treatments like thiopurines and anti-TNFα are linked to a markedly higher risk of developing lymphoma and skin cancer.
- The findings emphasize the need for tailored immunotherapy and ongoing cancer monitoring for those diagnosed with pIMID.
Bone destruction of orbital wall in idiopathic orbital inflammatory pseudotumor: does it always imply malignancy?
Int J Ophthalmol
September 2024
Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Aim: To assess the clinical presentations and outcomes of idiopathic orbital inflammatory pseudotumor (IOIP) patients with orbital wall bone destruction (OWBD) and to propose an expanded classification system that includes bone destruction.
Methods: The study retrospectively reviewed clinical presentations, imaging findings, treatment modalities, and outcomes of six patients diagnosed histopathologically with IOIP and OWBD at the Beijing Tongren Hospital, Capital Medical University between October 2018 and June 2021.
Results: Over two years, 6 (10%) of 60 IOIP patients at our hospital exhibited OWBD, but this may overrepresent severe cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!